| # | Drug | Count |
|---|---|---|
| 0 | SACITUZUMAB GOVITECAN | 229 |
| 1 | PACLITAXEL | 76 |
| 2 | PACLITAXEL (AIBUMIN-BOUND) | 61 |
| 3 | PALONOSETRON HYDROCHLORIDE | 55 |
| 4 | DEXAMETHASONE | 49 |
| 5 | DEXAMETHASONE 1.5 MG | 49 |
| 6 | ATEZOLIZUMAB | 45 |
| 7 | PEGFILGRASTIM | 43 |
| 8 | DOCETAXEL | 37 |
| 9 | DOCETAXEL ANHYDROUS | 37 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SACITUZUMAB GOVITECAN | 229 | 0.0474 |
| 1 | PALONOSETRON HYDROCHLORIDE | 55 | 0.0102 |
| 2 | SONIDEGIB | 17 | 0.0101 |
| 3 | PEGFILGRASTIM | 43 | 0.0036 |
| 4 | NALDEMEDINE | 4 | 0.0024 |
| 5 | PHENOBARBITAL SODIUM | 1 | 0.0024 |
| 6 | DEXAMETHASONE SODIUM PHOSPHATE | 24 | 0.0023 |
| 7 | GARADACIMAB | 1 | 0.0013 |
| 8 | ATEZOLIZUMAB | 45 | 0.0011 |
| 9 | GRANISETRON HYDROCHLORIDE | 11 | 0.0010 |
| # | Drug class | Count |
|---|---|---|
| 0 | Microtubule Inhibitor [EPC] | 104 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 70 |
| 2 | Corticosteroid [EPC] | 60 |
| 3 | Leukocyte Growth Factor [EPC] | 44 |
| 4 | Platinum-based Drug [EPC] | 34 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 33 |
| 6 | Alkylating Drug [EPC] | 32 |
| 7 | Histamine-2 Receptor Antagonist [EPC] | 28 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 28 |
| 9 | Kinase Inhibitor [EPC] | 25 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Aldehyde Dehydrogenase Inhibitor [EPC] | 1 | 0.0009 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 70 | 0.0007 |
| 2 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 6 | 0.0007 |
| 3 | Microtubule Inhibitor [EPC] | 104 | 0.0006 |
| 4 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 13 | 0.0006 |
| 5 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 6 | Neurokinin 3 Receptor Antagonist [EPC] | 1 | 0.0004 |
| 7 | Plasma Kallikrein Inhibitor [EPC] | 1 | 0.0004 |
| 8 | Estrogen Receptor Antagonist [EPC] | 14 | 0.0003 |
| 9 | Leukocyte Growth Factor [EPC] | 44 | 0.0003 |